BioNTech SE - ADR Financials

$103.76

$0.88 (0.86%)

As on 04-Sep-2026 16:00EDT

Market cap

$26,065 Mln

Revenue (TTM)

$2,643 Mln

P/E Ratio

--

P/B Ratio

1.3

Div. Yield

0 %

Annual
Quarterly

Income Statement (€ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	2,643.43	2,756.63	2,751.10	3,819.00	17,310.60	18,976.70
Cost of Revenue	771.34	616.47	541.30	599.80	2,995.00	2,911.50
Gross Profit	1,872.09	2,140.16	2,209.80	3,219.20	14,315.60	16,065.20
Operating Expenses	3,769.68	2,764.03	3,524.10	2,528.80	1,672.90	781.40
Operating Profit (EBIT)	-1,897.59	-623.87	-1,314.30	690.40	12,642.70	15,283.80
Other Income	--	--	--	--	--	--
Profit before Tax	-1,636.71	-1,009.33	-677.70	1,186.10	12,954.10	15,046.40
Provision for Tax	55.58	81.93	-12.40	255.80	3,519.70	4,753.90
Profit after Tax (Net Income)	-1,692.29	-1,091.26	-665.30	930.30	9,434.40	10,292.50
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	--	10,292.50

Liabilities (€ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	17,750.17	19,216.02	19,411.10	20,245.90	20,055.60	11,893.70
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	635.64	621.84	595.40	689.90	272.90	455.50
Current Liabilities	1,948.40	2,141.39	2,523.20	2,070.50	2,950.60	3,481.60
Total Liabilities	22,282.60	21,979.24	22,529.70	23,006.30	23,279.10	15,830.80

Assets (€ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	5,043.22	5,839.51	3,726.20	3,479.00	1,357.10	758.50
Current Assets	15,290.99	16,139.73	18,803.50	19,527.30	21,922.00	15,072.30
Total Assets	22,277.09	21,979.24	22,529.70	23,006.30	23,279.10	15,830.80
Total Debt*	315.97	267.29	254.20	219.10	212.20	301.50
Net Current Assets	13,348.10	14,004.30	16,280.30	17,456.80	18,971.40	11,590.70

Cashflow (€ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	438.00	207.70	5,371.40	13,577.40	889.70
Cash Flow from Investing Activities	--	-2,371.07	-2,081.20	-6,954.50	-35.30	-566.10
Cash from Financing Activities	--	-50.81	-45.90	-778.60	-1,419.30	94.20
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS (€)	--	-6.73	-4.45	-2.77	3.86	38.34
Cash EPS (€)	--	-7.78	-2.89	-1.53	4.62	38.84
Adjusted Book Value (€)	--	81.89	78.38	80.79	84.01	81.50
Dividend per Share (€)	--	--	--	--	--	--
Cash Flow per Share (€)	--	--	1.79	0.86	22.29	55.17
Free Cash Flow per Share (€)	--	--	1.10	-1.02	19.36	53.70

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	--	-5.57	-3.32	4.57	58.12
ROE (%)	--	-9.16	-5.65	-3.36	4.62	59.06
ROA (%)	--	-7.40	-4.90	-2.92	4.02	48.25
EBIT Margin (%)	--	-61.20	-36.12	-24.18	31.26	74.94
Net Margin (%)	--	-64.02	-39.59	-24.18	24.36	54.50
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	-8.16	0.00	-0.28	-0.78	-0.09
EBIT Growth (%)	--	-368.82	-49.71	-155.70	-90.80	-13.09
Net Profit Growth (%)	--	-390.80	-64.03	-171.51	-90.14	-8.34
EPS Growth (%)	--	-367.39	-0.61	-1.72	-0.90	-0.03
Book Value Growth (%)	--	-8.51	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.01	0.01	0.01	0.01	0.01
Short term debt to equity ratio	0.10	0.00	0.00	0.00	0.00	0.00
Current Ratio	--	7.85	7.54	7.45	9.43	7.43
Quick Ratio	--	7.80	7.49	7.34	9.26	7.28
Interest Coverage	--	-86.04	-73.00	-50.53	153.85	819.96

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	9.27	35.71	55.39	61.26	41.28
Asset Turnover	--	0.12	0.12	0.12	0.17	0.89
Receivable days	--	--	166.18	256.48	453.61	206.02
Inventory Days	--	--	116.71	216.26	242.76	57.45
Payable days	--	--	284.80	263.39	169.93	22.20
Cash Conversion Cycle	--	--	-1.92	209.34	526.44	241.26

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.